MedTrace Logo

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

NCT00083538 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-07-07

No results posted yet for this study

Summary

The purpose of this study is to determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.

Conditions

Interventions

DRUG

Dexamethasone

DRUG

Thalidomide

DRUG

Cisplatinum

DRUG

Adriamycin

DRUG

Cyclophosphamide

DRUG

Etoposide

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Van Rhee Frits, M.D. · UAMS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083538 on ClinicalTrials.gov